ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $800.27M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.07M
Average 1.91M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Enliven Therapeutics, Inc. NASDAQ:ELVN | $3.59B | $48.80 | Not rated | -28.4 | +110.00% |
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -46.71% |
Tyra Biosciences, Inc. NASDAQ:TYRA | $1.38B | $20.03 | Not rated | -13.4 | +18.71% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -26.00% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | $10.64 | Not rated | -24.1 | +12.47% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -45.36% |
Nuvectis Pharma, Inc. NASDAQ:NVCT | $696.03M | $20.24 | Not rated | -11.2 | +232.33% |
Janux Therapeutics, Inc. NASDAQ:JANX | $695.66M | $11.37 | Not rated | -7.6 | -64.28% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -43.78% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +39.44% |
Continue the stock analysis
Jump to another research area for this company.